Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Fructose Intestinal Gluconeogenesis

Touro University, California · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT07209202

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 20–55 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
40
US sites recruiting
1
Study start
March 2, 2026
Record last updated
March 6, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study will test the hypothesis that within a defined range of fructose intake, the ability to convert fructose to glucose (via gluconeogenesis) in the small intestine plays a protective role for the liver, shielding it from the deleterious effects of fructose. We will investigate whether this protective effect of the intestine is impaired in individuals with obesity.

Being studied: High fructose meal; Low fructose meal; 13C labeled fructose, oral; 13C labeled fructose, intravenous

Conditions: Healthy Participants; Obese But Otherwise Healthy Participants

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • BMI 30 to 38 kg/m2 (obese group) or BMI 19 to 25 kg/m2 (lean group)

Exclusion Criteria

  • Pregnancy or lactation within the past six months;
  • Type 1 or 2 diabetes mellitus (including fasting glucose ≥126 mg/dL, HgbA1c ≥6.5%);
  • History of liver disease or AST and ALT 2x above the upper limit of normal;
  • Fasting triglyceride > 300 mg/dl; total cholesterol levels above the 95th percentile for age and sex;
  • Hemoglobin (Hgb) \<12.5g/d or hematocrit\<3x Hgb value;
  • Report of HIV or hepatitis B or C infection;
  • History of cancer, other than basal cell or squamous cell carcinoma or kidney disease stage 3 or higher or patients currently on dialysis;
  • Use of any anti-diabetic medications or hypolipidemic agents in the past six months;
  • History of surgical procedure for obesity;
  • Change in body weight >5% in the past six months (by self-report);
  • History of other conditions known to affect insulin sensitivity and lipid metabolism (e.g., polycystic ovary syndrome), history of galactosemia, hereditary fructose intolerance, or who test positive for fructose malabsorption at screening;
  • Known intolerance to acetaminophen.

Recruiting US locations

  • Touro University California

    Vallejo, CA 95492

    Site contact: Sally Chiu, PhD · schiu2@touro.edu

Study contacts (from the official record)

  • Sally Chiu, PhD · 707-638-5404 · schiu2@touro.edu
  • Lisa Johnson, RN · ljohnson19@touro.edu
All weight loss studies in California →
Fructose Intestinal Gluconeogenesis (NCT07209202) | Bored Studies